Quinine plus sulfadoxine-pyrimethamine — Competitive Intelligence Brief

Quinine plus sulfadoxine-pyrimethamine (Quinine plus sulfadoxine-pyrimethamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Plasmodium DNA/protein synthesis; dihydrofolate reductase; dihydropteroate synthase Infectious Disease Small molecule

Target snapshot

Quinine plus sulfadoxine-pyrimethamine (Quinine plus sulfadoxine-pyrimethamine) — Albert Schweitzer Hospital. This combination uses quinine to inhibit parasite protein synthesis and sulfadoxine-pyrimethamine to block folate metabolism in malaria parasites, providing synergistic antimalarial activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Quinine plus sulfadoxine-pyrimethamine TARGET	Quinine plus sulfadoxine-pyrimethamine	Albert Schweitzer Hospital	marketed	Antimalarial combination	Plasmodium DNA/protein synthesis; dihydrofolate reductase; dihydropteroate synthase
IPTp-DP	IPTp-DP	Kenya Medical Research Institute	marketed	Antimalarial combination therapy	Plasmodium falciparum (malaria parasite)
Artemether + Lumefantrine	Artemether + Lumefantrine	GlaxoSmithKline	marketed	Antimalarial combination	Plasmodium falciparum hemoglobin metabolism and heme detoxification pathway
Chloroquine + Primaquine	Chloroquine + Primaquine	U.S. Army Medical Research and Development Command	marketed	Antimalarial combination	Plasmodium parasite heme metabolism and mitochondrial function
artemisinin/naphthoquine	artemisinin/naphthoquine	Ifakara Health Institute	marketed	Antimalarial combination	Plasmodium falciparum heme metabolism and mitochondrial electron transport
chlorproguanil-dapsone plus artesunate	chlorproguanil-dapsone plus artesunate	Centers for Disease Control and Prevention	marketed	Antimalarial combination	Dihydrofolate reductase (chlorproguanil/dapsone); mitochondrial function (artesunate)
Amodiaquine plus sulphadoxine-pyrimethamine combination	Amodiaquine plus sulphadoxine-pyrimethamine combination	Centre for Global Health Research, Ghana	marketed	Antimalarial combination	Plasmodium dihydrofolate reductase, dihydropteroate synthase, and hemozoin formation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class